

ACTIVE LEARNING TEMPLATE: **Medication**

STUDENT NAME Emily Johnson

MEDICATION Influenza virus vaccine (Inactivated)

REVIEW MODULE CHAPTER \_\_\_\_\_

CATEGORY CLASS Vaccine, inactivated (viral)

**PURPOSE OF MEDICATION**

**Expected Pharmacological Action**

Promotes immunity to seasonal influenza virus by inducing specific antibody production. Preparations from previous seasons may not be used.

**Therapeutic Use**

IM injection that provides protection from seasonal influenza and reduces severity if infection occurs.

**Complications/adverse reactions/Side Effects**

Anorexia (B-231.), Bruising at injection site, pain at injection site, tenderness at injection site, Drowsiness, fatigue, headache, myalgia, nausea, cough, muscle weakness.

**Medication Administration**

Suspension IM:  
Shake well prior to use, deltoid preferred  
adults  $\geq 65$  yo IM .05 mL/dose  
1 dose per season  
adults  $< 65$  yo IM .5 mL/dose  
1 dose per season  
infants  $\geq 6$  months IM .5 mL/dose  
1 or 2 doses per season

**Contraindications/Precautions**

Severe allergic reaction to any part of formula, hypersensitivity to egg protein, oculorespiratory syndrome;  
Altered immunocompetence: postpone vaccination during periods of chemo/radiation response.

**Nursing Interventions**

Assess for pain, muscle tenderness, redness, inflammation/swelling at injection site.  
Assess pt for drowsiness or fatigue.

**Interactions**

Acetaminophen: may decrease therapeutic effects of vaccines  $\rightarrow$  avoid routine prophylactic use before or during admin.  
ANTI-CD20 B-cell Depleting therapies: may  $\downarrow$  therapeutic effects of Influenza virus vaccines  $\rightarrow$  Administer 2 weeks prior to starting CD20.

**Client Education**

Vaccination may not result in effective immunity in all pts. Response depends on various factors.

**Evaluation of Medication Effectiveness**

No pain or discomfort at injection site or all together, no sickness or cough presented 1 hr after admin.

# ACTIVE LEARNING TEMPLATE: Medication

STUDENT NAME Emily Johnson (23-valent) (Pneumo 23)  
MEDICATION Pneumococcal Polysaccharide Vaccine REVIEW MODULE CHAPTER \_\_\_\_\_  
CATEGORY CLASS Vaccine, inactivated (bacterial)

## PURPOSE OF MEDICATION

### Expected Pharmacological Action

Pneumococcal polysaccharide 23-valent is an inactive bacterial vaccine that induces active immunization to the serotypes contained in the vaccine

### Therapeutic Use

Pneumococcal disease prevention

### Complications

Pain, redness, swelling, headache, feeling tired or weak, muscle or joint pain, chills

- Signs of allergic reaction, trouble breathing, swallowing
- Tissue necrosis at injection site

### Medication Administration

doses admin  $\leq 4$  days  
minimum interval or age  
IM SUBQ: 0.5mL/dose  
different valents of vaccine depending on age or risk factors have many different routes

### Contraindications/Precautions

- Severe allergic reaction to pneumococcal vaccine or any component in formula
- Acute illness, bleeding disorders, cardiovascular diseases where systemic reaction may pose significant risk, CSF leaks

### Nursing Interventions

- monitor for hyper sensitivity and syncope for 15 mins following admin
- if seizure-like activity associated w/ syncope starts put pt in supine or Trendelenburg to reestablish adequate cerebral perfusion

### Interactions

- Anti-CD20 B cell depleting therapies
- Adarsagene autoemcel: may ↑ toxic effects
- Corticosteroids (systemic)
- Immunosuppressants

### Evaluation of Medication Effectiveness

no signs of hypersensitivity after 15 min admin  
no signs of seizure-like activity, irritation at IM site, no signs of allergic reaction

### Client Education

Vaccine is not fully protective to obtaining pneumococcal, but it can help decrease symptoms if you do get sick